Buy & Sell C3.ai Inc (AI) – C3.ai Inc Price Today
Aura AI Summary
Key Stats
- $1.60BMarket Cap
- TechnologySector
- -12.36%3M Drawdown
- $986.01MEnterprise Value
- -Dividend Yield
- 91% Buy | 9% SellTrading Activity
- 127 daysTypical Hold Time
C3.ai Inc (AI) is currently valued at a market capitalization of $1.60B, with an enterprise value of $986.01M. Over the past 52 weeks, C3.ai Inc has traded between a low of $7.76 and a high of $29.16, highlighting its annual price range. Over the past three months, C3.ai Inc has recorded a drawdown of -12.36%, reflecting recent price volatility. On average, investors hold C3.ai Inc for approximately 127 days, indicating typical investor behavior on the platform.
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Most Recent News
Defiance ETFs launches SPCQ, a 2x inverse leveraged ETF targeting daily SpaceX stock declines.
Defiance ETFs introduced the Defiance Daily Target 2X Short SpaceX ETF (SPCQ), designed to provide investors with double inverse exposure to SpaceX's daily stock price movements. This ETF aims to deliver -200% of SpaceX's daily returns, allowing inve...

Halper Sadeh LLC probes fairness of recent major company sales and mergers for shareholders.
Halper Sadeh LLC, an investor rights law firm, is investigating whether shareholders of Open Lending Corporation, Nuvalent, Organon & Co., and SUNation Energy are receiving fair deals in their companies' recent sales or mergers. The firm suggests ins...

Global GLP-1 receptor agonist market to reach $95.3B by 2035, growing at 12.1% CAGR driven by diabetes and obesity demand.
The global GLP-1 receptor agonist market, used primarily for type 2 diabetes and obesity management, is projected to grow from $28.7 billion in 2025 to $95.3 billion by 2035, at a compound annual growth rate of 12.1%. Growth is fueled by rising diabe...
